

# Jaime Sanz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/925636/publications.pdf>

Version: 2024-02-01

151  
papers

4,640  
citations

126708

33  
h-index

133063

59  
g-index

153  
all docs

153  
docs citations

153  
times ranked

4947  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1800-1810.	13.9	455
2	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	1.3	218
3	Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. <i>Leukemia</i> , 2015, 29, 1891-1900.	3.3	199
4	Analysis of Risk Factors for Outcomes After Unrelated Cord Blood Transplantation in Adults With Lymphoid Malignancies: A Study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2009, 27, 256-263.	0.8	195
5	Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. <i>Haematologica</i> , 2008, 93, 67-74.	1.7	188
6	Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. <i>Bone Marrow Transplantation</i> , 2012, 47, 1287-1293.	1.3	124
7	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1114-1125.	1.3	97
8	Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. <i>Leukemia</i> , 2014, 28, 779-786.	3.3	95
9	Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients. <i>Bone Marrow Transplantation</i> , 2007, 39, 555-561.	1.3	91
10	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i> -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	1.7	91
11	Bone Marrow-Derived Cells from Male Donors Do Not Contribute to the Endometrial Side Population of the Recipient. <i>PLoS ONE</i> , 2012, 7, e30260.	1.1	85
12	Cord Blood Transplantation from Unrelated Donors in Adults with High-Risk Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 86-94.	2.0	79
13	Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers. <i>JAMA Oncology</i> , 2019, 5, 1739.	3.4	76
14	Challenges in Clinical Metaproteomics Highlighted by the Analysis of Acute Leukemia Patients with Gut Colonization by Multidrug-Resistant Enterobacteriaceae. <i>Proteomes</i> , 2019, 7, 2.	1.7	71
15	New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2013, 121, 1059-1064.	0.6	69
16	Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. <i>Leukemia and Lymphoma</i> , 2006, 47, 1488-1494.	0.6	68
17	Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. <i>Journal of Hematology and Oncology</i> , 2020, 13, 46.	6.9	68
18	EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. <i>Bone Marrow Transplantation</i> , 2014, 49, 397-402.	1.3	63

#	ARTICLE	IF	CITATIONS
19	Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2014, 123, 2960-2967.	0.6	62
20	Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. <i>Bone Marrow Transplantation</i> , 2020, 55, 641-648.	1.3	58
21	Incidence, Risk Factors, and Outcome of Cytomegalovirus Infection and Disease in Patients Receiving Prophylaxis with Oral Valganciclovir or Intravenous Ganciclovir after Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 730-740.	2.0	54
22	Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen. <i>Haematologica</i> , 2014, 99, 1509-1515.	1.7	48
23	Impact on Outcomes of Human Leukocyte Antigen Matching by Allele-Level Typing in Adults with Acute Myeloid Leukemia Undergoing Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 106-110.	2.0	48
24	Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 584-588.	2.0	45
25	Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. <i>Journal of Hematology and Oncology</i> , 2020, 13, 87.	6.9	44
26	Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Journal of Hematology and Oncology</i> , 2017, 10, 20.	6.9	43
27	Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. <i>Journal of Hematology and Oncology</i> , 2018, 11, 110.	6.9	41
28	Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. <i>Neurological Sciences</i> , 2017, 38, 1213-1221.	0.9	40
29	Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. <i>Clinical Cancer Research</i> , 2020, 26, 6475-6482.	3.2	40
30	Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. <i>Oncotarget</i> , 2018, 9, 3379-3393.	0.8	40
31	Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 142-150.	0.6	38
32	Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 1894-1903.	2.9	36
33	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 358-366.	2.0	36
34	Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 532-535.	1.3	36
35	Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 957-966.	2.0	35
36	Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2017, 92, 997-1003.	2.0	34

#	ARTICLE	IF	CITATIONS
37	Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2021, 35, 215-224.	3.3	34
38	Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis. <i>Bone Marrow Transplantation</i> , 2015, 50, 1465-1472.	1.3	33
39	Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1197-1206.	0.6	33
40	Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. <i>Leukemia and Lymphoma</i> , 2015, 56, 656-662.	0.6	32
41	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 218-224.	1.3	32
42	Myeloablative Cord Blood Transplantation in Adults with Acute Leukemia: Comparison of Two Different Transplant Platforms. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1725-1730.	2.0	31
43	Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience. <i>Bone Marrow Transplantation</i> , 2014, 49, 1084-1088.	1.3	31
44	Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1589-1595.	2.0	30
45	Bloodstream Infections in Adult Patients Undergoing Cord Blood Transplantation from Unrelated Donors after Myeloablative Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 755-760.	2.0	30
46	Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Espa�ol De Trasplante de Medula Osea en Ni�os (GETMON) and the Grupo Espa�ol de Trasplante Hematopoyetico (GETH). <i>Transfusion Medicine Reviews</i> , 2018, 32, 179-185.	0.9	30
47	Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies. <i>Haematologica</i> , 2009, 94, 827-832.	1.7	29
48	Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1818-1824.	2.0	29
49	Central nervous system involvement at first relapse in patients with acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 1375-1379.	1.7	28
50	LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. <i>Bone Marrow Transplantation</i> , 2007, 39, 41-47.	1.3	27
51	Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2021, 14, 84.	6.9	27
52	Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e14-e25.	2.2	27
53	Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT. <i>Journal of Internal Medicine</i> , 2018, 283, 178-189.	2.7	26
54	Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. <i>Lancet Haematology</i> , 2021, 8, e205-e215.	2.2	26

#	ARTICLE	IF	CITATIONS
55	Unexpected Postmortem Diagnosis of Acanthamoeba Meningoencephalitis Following Allogeneic Peripheral Blood Stem Cell Transplantation. <i>American Journal of Transplantation</i> , 2008, 8, 1562-1566.	2.6	25
56	Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation. <i>Annals of Hematology</i> , 2021, 100, 541-553.	0.8	25
57	Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 843-851.	3.2	25
58	Impact of Graft-versus-Host Disease Prophylaxis on Outcomes after Myeloablative Single-Unit Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1387-1392.	2.0	24
59	Infections of the Central Nervous System after Unrelated Donor Umbilical Cord Blood Transplantation or Human Leukocyte Antigen-Matched Sibling Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 134-139.	2.0	24
60	Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections. <i>Transplant Infectious Disease</i> , 2018, 20, e12926.	0.7	24
61	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. <i>Bone Marrow Transplantation</i> , 2020, 55, 2147-2159.	1.3	24
62	Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 887-894.	1.3	23
63	Epstein-Barr virus-associated posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation. <i>Current Opinion in Oncology</i> , 2014, 26, 677-683.	1.1	23
64	Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2018, 97, 161-167.	0.8	22
65	Immunofluorescent analysis with the anti-PML monoclonal antibody PG-M3 for rapid and accurate genetic diagnosis of acute promyelocytic leukemia. <i>Annals of Hematology</i> , 2004, 83, 687-690.	0.8	21
66	Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2021, 223, 1564-1575.	1.9	21
67	Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2007, 48, 2367-2374.	0.6	19
68	Effect of CD8+ Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1744-1750.	2.0	19
69	Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease. <i>European Journal of Haematology</i> , 2016, 96, 128-135.	1.1	19
70	OUTCOME OF ANTIFUNGAL COMBINATION THERAPY FOR INVASIVE MOLD INFECTIONS IN HEMATOLOGICAL PATIENTS IS INDEPENDENT OF THE CHOSEN COMBINATION. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012011.	0.5	18
71	INFECTIOUS COMPLICATIONS AFTER UMBILICAL CORD-BLOOD TRANSPLANTATION FROM UNRELATED DONORS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016051.	0.5	18
72	Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH). <i>European Journal of Haematology</i> , 2019, 102, 465-471.	1.1	18

#	ARTICLE	IF	CITATIONS
73	Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT. <i>Blood Cancer Journal</i> , 2019, 9, 46.	2.8	18
74	Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission. <i>Bone Marrow Transplantation</i> , 2021, 56, 1272-1280.	1.3	18
75	Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13158.	0.7	17
76	Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia. <i>Journal of Infection</i> , 2019, 78, 393-401.	1.7	17
77	Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated donor cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 592-601.	1.2	17
78	A Study of Incidence and Characteristics of Infections in 476 Patients from a Single Center Undergoing Autologous Blood Stem Cell Transplantation. <i>International Journal of Hematology</i> , 2007, 86, 186-192.	0.7	16
79	Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2014, 99, 378-384.	1.7	16
80	T Cell-Depleted Related HLA-Mismatched Peripheral Blood Stem Cell Transplantation as Salvage Therapy for Graft Failure after Single Unit Unrelated Donor Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1060-1063.	2.0	16
81	Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2014, 93, 43-46.	0.8	16
82	Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. <i>Annals of Hematology</i> , 2019, 98, 2081-2088.	0.8	16
83	Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions. <i>Experimental Hematology</i> , 2018, 62, 24-32.	0.2	15
84	Detection of plasmid-mediated colistin resistance, mcr-1 gene, in Escherichia coli isolated from high-risk patients with acute leukemia in Spain. <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 605-609.	0.8	15
85	Aproximación a la enfermedad injerto contra huésped cutánea. <i>Actas Dermo-sifiligráficas</i> , 2016, 107, 183-193.	0.2	14
86	Análisis retrospectivo del papel de la fototerapia en la enfermedad injerto contra huésped crónica cutánea. Revisión de la literatura. <i>Actas Dermo-sifiligráficas</i> , 2015, 106, 651-657.	0.2	13
87	Advances in haploidentical stem cell transplantation for hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 1766-1775.	0.6	13
88	Genomic characterization of Citrobacter freundii strains coproducing OXA-48 and VIM-1 carbapenemase enzymes isolated in leukemic patient in Spain. <i>Antimicrobial Resistance and Infection Control</i> , 2019, 8, 167.	1.5	13
89	Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders. <i>Aids</i> , 2019, 33, 1441-1447.	1.0	13
90	The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey. <i>Bone Marrow Transplantation</i> , 2020, 55, 431-440.	1.3	13

#	ARTICLE	IF	CITATIONS
91	Impact on outcomes of human leukocyte antigen matching by allele-level typing in adults with acute myeloid leukemia undergoing umbilical cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 106-10.	2.0	13
92	Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 76.	6.9	12
93	Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS. <i>Bone Marrow Transplantation</i> , 2016, 51, 961-966.	1.3	11
94	Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia: A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2017, 92, 18-22.	2.0	11
95	ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 394-399.	1.3	10
96	Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 507-513.	2.0	10
97	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2194-2202.	1.3	10
98	Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 1389-1398.	1.3	10
99	Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain. <i>Advances in Therapy</i> , 2017, 34, 2104-2119.	1.3	9
100	Reduced-Intensity versus Myeloablative Conditioning in Cord Blood Transplantation for Acute Myeloid Leukemia (40-60 years) across Highly Mismatched HLA Barriers: On Behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2098-2104.	2.0	9
101	Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients?. <i>Transplant Infectious Disease</i> , 2021, 23, e13602.	0.7	9
102	Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin. <i>Annals of Hematology</i> , 2017, 96, 1077-1084.	0.8	8
103	Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2021, 127, 2507-2514.	2.0	8
104	Significance of Increased Blastic-Appearing Cells in Bone Marrow Following Myeloablative Unrelated Cord Blood Transplantation in Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 388-395.	2.0	7
105	Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2438-2446.	2.0	7
106	Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 23, e13507.	0.7	7
107	Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13301.	0.7	7
108	The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation. <i>Journal of Infection</i> , 2020, 80, 333-341.	1.7	7

#	ARTICLE	IF	CITATIONS
109	Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 614215.	1.3	7
110	Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 710.e1-710.e10.	0.6	7
111	Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 1887-1890.	0.2	6
112	Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia. <i>Blood Advances</i> , 2017, 1, 1047-1055.	2.5	6
113	Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>European Journal of Health Economics</i> , 2018, 19, 627-636.	1.4	6
114	Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 999.e1-999.e10.	0.6	6
115	Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 204.e1-204.e10.	0.6	6
116	Impact of HLA class I and class II DNA high-resolution HLA typing on clinical outcome in adult unrelated stem cell transplantation after in vivo T-cell depletion with alemtuzumab. <i>Transplant Immunology</i> , 2007, 18, 179-185.	0.6	5
117	Prognostic value of cytogenetics in adult patients with Philadelphia-negative acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2012, 91, 19-25.	0.8	5
118	One or two umbilical cord blood cell units? Caveat emptor. <i>Bone Marrow Transplantation</i> , 2017, 52, 341-343.	1.3	5
119	Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation. <i>European Journal of Haematology</i> , 2019, 103, 172-177.	1.1	5
120	Common seasonal respiratory virus infections in allogeneic stem cell transplant recipients during the SARS-COV-2 pandemic. <i>Bone Marrow Transplantation</i> , 2021, 56, 2212-2220.	1.3	5
121	Umbilical cord blood transplantation from unrelated donors in adult patients with chronic myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 217-222.	0.7	4
122	Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment. <i>Revista Iberoamericana De Micologia</i> , 2015, 32, 185-189.	0.4	4
123	One-Unit versus Two-Unit Cord-Blood Transplantation. <i>New England Journal of Medicine</i> , 2015, 372, 287-288.	13.9	4
124	The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial). <i>Bone Marrow Transplantation</i> , 2016, 51, 1404-1407.	1.3	4
125	Tratamiento de la enfermedad de injerto contra huésped crónica esclerodermiforme con imatinib: una perspectiva dermatológica. <i>Actas Dermo-sifiliográficas</i> , 2018, 109, 241-247.	0.2	4
126	T lymphocytes as therapeutic arsenal for patients with hematological malignancies. <i>Current Opinion in Oncology</i> , 2018, 30, 425-434.	1.1	4



#	ARTICLE	IF	CITATIONS
127	Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission. <i>Journal of Internal Medicine</i> , 2019, 285, 446-454.	2.7	4
128	Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen. <i>European Journal of Haematology</i> , 2019, 102, 331-340.	1.1	4
129	Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?. <i>Transplant Infectious Disease</i> , 2020, 22, e13440.	0.7	4
130	Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 261.e1-261.e7.	0.6	4
131	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. <i>EJHaem</i> , 2021, 2, 236-248.	0.4	4
132	Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 572-578.	1.3	4
133	Neoplasias hematológicas: interpretación de los hallazgos pulmonares en la tomografía computarizada torácica. <i>Radiología</i> , 2015, 57, 455-470.	0.3	3
134	Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain. <i>Pharmacoeconomics - Open</i> , 2019, 3, 229-235.	0.9	3
135	Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients. <i>Mycoses</i> , 2019, 62, 418-427.	1.8	3
136	Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 83-87.	2.0	3
137	High Heterogeneity of Multidrug-Resistant <i>Enterobacteriaceae</i> Fecal Levels in Hospitalized Patients Is Partially Driven by Intravenous $\beta$ -Lactams. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	3
138	Community acquired respiratory virus infections in adult patients undergoing umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 2261-2269.	1.3	3
139	Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors. <i>Bone Marrow Transplantation</i> , 2021, 56, 992-996.	1.3	3
140	Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110381.	1.1	3
141	Umbilical Cord Blood Transplantation in Children and Adults. , 2019, , 473-478.		3
142	Clinical significance of <i>Pneumocystis jirovecii</i> DNA detection by real-time PCR in hematological patient respiratory specimens. <i>Journal of Infection</i> , 2020, 80, 578-606.	1.7	2
143	Ex vivo T cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2021, 106, 114-125.	1.1	2
144	Allogeneic hematopoietic stem cell transplant recipients in Spain: Human leukocyte antigen characteristics and diversity by high-resolution analysis. <i>Hla</i> , 2021, 97, 198-213.	0.4	2

#	ARTICLE	IF	CITATIONS
145	Extracorporeal photopheresis vs standard therapies for steroidâ€refractory chronic graftâ€vsâ€host disease: Pharmacoeconomic assessment of hospital resource use in Spain. Journal of Clinical Apheresis, 2021, 36, 612-620.	0.7	2
146	Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. Leukemia and Lymphoma, 2020, 61, 1823-1832.	0.6	1
147	An investigation of the potential association between gastrointestinal viral and bacterial infection and development of intestinal acute graft versus host disease following allogeneic hematopoietic stem cell transplantation. Journal of Medical Virology, 2021, 93, 4773-4779.	2.5	1
148	Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain. European Journal of Haematology, 2021, 106, 724-733.	1.1	1
149	Cambios en el estado nutricional, composiciÃ³n corporal y sintomatologÃa asociada en pacientes hospitalizados sometidos a trasplante de mÃ©dula Ãsea: estudio longitudinal prospectivo. Revista Espanola De Nutricion Humana Y Dietetica, 2021, 25, 154-164.	0.1	1
150	Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT. Bone Marrow Transplantation, 2022, , .	1.3	1
151	Single or Double Cord Blood Unit for Transplant: What Have We Learned?. , 2017, , 37-45.		0